Christopher Daniels, MD
Interventional Cardiology · Thomasville, GANPI 1952519670
Payments from drug & device makers
Across 749 payments — averaging $553.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$172K
- Johnson & Johnson$85K
- Boehringer Ingelheim Pharma GmbH & Co.kg$50K
- Merck$33K
- Boehringer Ingelheim International GmbH$32K
- Angiodynamics, Inc.$13K
- plus $32K from 34 others
What the payments were for
- Speaking & faculty fees$79,33266%
- Travel & lodging$11,2309%
- Food & beverage$17,55915%
- Education$2130%
- Other$12,15010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$82,306
- Auryon Laser System 100-120 Vac$12,399
- AVEIR$3,197
- Peripheral Orbital Atherectomy System$2,112
- Impella$857
- Micra$524
- Coronary Orbital Atherectomy System$482
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$327
- Omnilink Elite vascular stent system$298
- AVVIGO Guidance System$225
- CoreValve Evolut$188
- CARDIOMEMS$148
- AZURE XT DR MRI SURESCAN$148
- LIMFLOW SYSTEM$140
- Indigo System$127
- MyCareLink$127
- Diamondback Peripheral$122
- Diamondback Coronary$122
- RotarexS 6 F x 135 cm$121
- ATTAIN PERFORMA MRI SURESCAN$112
How this compares
$414,486 in reported general payments places this provider in the 90th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 72 | $1,584,144 |
| EliquisApixaban | 605 | $470,442 |
| EntrestoSacubitril/Valsartan | 297 | $220,787 |
| FarxigaDapagliflozin Propanediol | 280 | $196,404 |
| XareltoRivaroxaban | 246 | $177,483 |
| Repatha SureclickEvolocumab | 159 | $112,409 |
| BrilintaTicagrelor | 155 | $97,638 |
| JardianceEmpagliflozin | 108 | $89,186 |
| Ranolazine ErRanolazine | 468 | $31,139 |
| MultaqDronedarone Hcl | 18 | $21,431 |
| Metoprolol Succinate | 1,156 | $12,734 |
| VascepaIcosapent Ethyl | 31 | $11,372 |
| CorlanorIvabradine Hcl | 13 | $10,321 |
| EdarbiAzilsartan Medoxomil | 20 | $8,567 |
| Atorvastatin Calcium | 910 | $7,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $408 | $2,054,586677 claims |
| AstraZenecaFarxiga, Brilinta | $1,040 | $294,042435 claims |
| NovartisEntresto | $171,645 | $220,787297 claims |
| Johnson & JohnsonXarelto | $84,714 | $177,483246 claims |
| Boehringer IngelheimJardiance | $270 | $89,186108 claims |
| Sanofi-aventis U.S. LLCMultaq | $128 | $21,43118 claims |
| AmgenCorlanor | $427 | $10,32113 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $60 | $8,56720 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $43 | $5,53512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Thomasville
- Byron SizemoreThomasville$1.1M
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- Megan CoylewrightCalhoun$2.3M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Amar PatelMarietta$1.8M
- Vivek RajagopalAtlanta$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.